Peer-influenced content. Sources you trust. No registration required. This is HCN.
In this Q&A, Dr. Gautam Borthakur from the University of Texas MD Anderson Cancer Center talks with Clinical Advances in Hematology & Oncology about the goals, treatment options (including tailored treatment), differences in de novo vs. therapy-related, and other suggestions in patients with core-binding factor acute myeloid leukemia (AML).
Hematology November 24th 2020
DIET & NUTRITION 
PATIENT EDUCATION 
OBESITY/WEIGHT MANAGEMENT 
EXERCISE/TRAINING 
LEGAL MATTERS 
GUIDELINES/RECOMMENDATIONS